ADDF in the News

Karen Harris, Chief Financial Officer & Head of Mission Related Investments shares insight into ADDF’s investment strategy built around a venture philanthropy model and the growing biopharma interest in Alzheimer’s research.

Mark Roithmayr, CEO joined leaders from biopharma, policy, and research in Riyadh to discuss the current treatment and prevention landscape for Alzheimer’s disease.

Dr. Howard Fillit provides commentary on Biogen's decision to abandon Aduhelm, noting how this was more of a commercial than a scientific decision, and offering insights on how the handling of the program led to uncertainty about the drug.

In an article on blood-based biomarkers, Dr. Howard Fillit is quoted throughout, citing the JPAD Special Edition featuring ADDF-funded scientists and the future of lab-developed tests (LDTs), as well as the importance of biomarkers for precision medicine and how this treatment approach will be the key to reaching 100% slowing of cognitive decline.

Dr. Howard Fillit weighs in on the FDA’s decision to hold an Advisory Committee for donanemab, noting that the decision isn’t a setback, but rather the agency doing its due diligence, and offers background on the trial design.